Ibio Inc (NYSEAMERICAN: IBIO), a key player in the biotech and biologics space, has moved ahead by leveraging its proprietary plant-based Protein Expression System.
Adding anti-cancer targets: Ibio Inc (NYSEAMERICAN: IBIO) announced that the company would establish Oncology Drug Discovery Pipeline by adding three an-cancer targets of therapeutic candidates. This development or addition strengthens the company’s new drug discovery capabilities published a few weeks ago. As per Ibio, its efforts to change the drug development process through its proprietary plant-based FastPharming Protein expression system reduce the overall cost and time from the start to the clinical stage. The company is looking to partner with a leader in a technology partner to help achieve its vision. Furthermore, the company has agreed with FairJourney Biologics S.A. Ibio is expected to gain access to unique display technologies and proprietary antibodies libraries as per the agreement. As per the industry, with the access of FairJourney technology, Ibio is expected to strengthen its markets position in Drug Discvery.
Develop differentiated cancer therapeutic antibodies: The company stated that the technology provided with FairJourney is expected to enable Ibio to develop differentiated cancer therapeutic antibodies quickly. In addition, these antibodies will come improved antibody-dependent cell-mediated cytotoxicity or ADCC. FairJourney is a leading technology provider for antibody discovery. Its journey in space has grown rapidly in the last few years. A few of its undisclosed collaborations with other players have rapidly moved towards the clinic, which is a significant achievement for any technology provider. FairJourney collaborates with an innovator like iBio, has the experience to change the bioprocess paradigm with the help of its proprietary technologies to improve human anti-cancer antibody development. As per the company, its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development (proprietary technology) and Manufacturing Services coupled with Glycaneering Development Services to develop recombinant protein design.